STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Clinical trials for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 23:20 UTC
-
Engineered immune cells take on deadly skin cancer
Disease control OngoingThis early-phase study tests whether giving patients with advanced melanoma their own genetically modified T-cells, followed by high-dose interleukin-2, is safe and feasible. The T-cells are altered in the lab to resist a protein that normally stops them from attacking tumors. Ab…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New combo therapy shows promise for melanoma patients who failed previous treatment
Disease control OngoingThis study tests a combination of two drugs—T-VEC, a virus-based therapy that attacks tumors, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in people with advanced melanoma that has worsened after prior treatment. About 43 participants with stage I…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Triple threat: new drug cocktail takes on tough melanoma
Disease control OngoingThis study tests whether combining an immunotherapy drug (nivolumab) with two targeted drugs (either dabrafenib + trametinib or encorafenib + binimetinib) can shrink or control advanced melanoma that has spread to the brain or other organs. About 52 adults with a specific gene mu…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
New hope for tough melanoma: drug targets Cancer's growth signals
Disease control OngoingThis study tests a drug called ibrutinib in people with stage IV melanoma (skin cancer that has spread) that did not get better with other treatments. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink tumors…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Double immune attack: new combo therapy shows promise for tough melanoma
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Experimental combo aims to starve cancer cells in Late-Stage tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Can a drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either the combination or ipilimumab alone. The main goal was to see if the …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:09 UTC
-
Major trial tests immune drug against standard therapy for High-Risk melanoma
Disease control OngoingThis large phase 3 study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. Over 1,600 patients with high-risk stage III or IV melanoma that had been completely removed took part. …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Could a drug holiday work as well as continuous treatment for melanoma?
Disease control OngoingThis study tests whether taking a break from two targeted melanoma drugs (dabrafenib and trametinib) works as well as taking them every day. About 280 people with advanced BRAF-mutant melanoma that cannot be removed by surgery are participating. The goal is to see if intermittent…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug combo targets tumor blood supply and growth
Disease control OngoingThis early-phase study tested two experimental drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and check for side effects. The drugs work by blocking blood vessel gr…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New drug shows promise in halting advanced melanoma growth
Disease control OngoingThis phase II trial tests a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. The study looks at side effects and how long patients live, aiming to control the disease rather than cure it.
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
Two-Drug cocktail shows promise for Tough-to-Treat melanoma
Disease control OngoingThis early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes cancer cells need to grow)—in people with advanced melanoma that cannot be removed by surgery. The main g…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Triple therapy may boost survival in advanced melanoma
Disease control OngoingThis study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will receive either the two-drug or three-drug co…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Could breathing in a cancer drug shrink lung tumors?
Disease control OngoingThis early-phase trial tests an inhaled form of the immune-boosting drug aldesleukin (IL-2) in 70 people whose cancer has spread to the lungs. The goal is to find the safest and most effective dose, and to see if it can shrink tumors. Participants have cancers like melanoma, kidn…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC